This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sermet-Gaudelus, I.
Right arrow Articles by Hennequin, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sermet-Gaudelus, I.
Right arrow Articles by Hennequin, C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2001, p. 1937-1938, Vol. 45, No. 6
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.6.1937-1938.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Sputum Itraconazole Concentrations in Cystic Fibrosis Patients

I. Sermet-Gaudelus,1,* A. Lesne-Hulin,2 G. Lenoir,1 E. Singlas,2 P. Berche,3 and C. Hennequin3

Service de Pédiatrie Générale,1 Pharmacie,2 and Service de Microbiologie,3 Hôpital Necker-Enfants Malades, 75015 Paris, France

Received 30 October 2000/Returned for modification 27 November 2000/Accepted 22 March 2001

Itraconazole diffusion in sputum was studied in 11 cystic fibrosis patients with allergic bronchopulmonary aspergillosis. There was a high interindividual variability in sputum itraconazole concentration and sputum/serum drug concentration ratio. Three children had sputum drug concentrations before oral administration that were lower than the itraconazole MIC at which 90% of Aspergillus fumigatus strains were inhibited, although their serum drug concentrations were within the therapeutic range.

* Corresponding author. Mailing address: Service de Pédiatrie Générale, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75015 Paris, France. Phone: (33)1 44 49 38 73. Fax: (33)1 47 83 32 26. E-mail: sermet-gaudelus{at}necker.fr.

Antimicrobial Agents and Chemotherapy, June 2001, p. 1937-1938, Vol. 45, No. 6
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.6.1937-1938.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Conway, S. P., Etherington, C., Peckham, D. G., Brownlee, K. G., Whitehead, A., Cunliffe, H. (2004). Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. J Antimicrob Chemother 53: 841-847 [Abstract] [Full Text]  
  • Sullivan, K. M., Dykewicz, C. A., Longworth, D. L., Boeckh, M., Baden, L. R., Rubin, R. H., Sepkowitz, K. A. (2001). Preventing Opportunistic Infections After Hematopoietic Stem Cell Transplantation: The Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and Beyond. ASH Education Book 2001: 392-421 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»